These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31770362)

  • 1. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):177-184. PubMed ID: 36384763
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 5. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

  • 6. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 7. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
    Zhang YS; Zheng YD; Yuan Y; Chen SC; Xie BC
    Front Endocrinol (Lausanne); 2021; 12():735824. PubMed ID: 34721294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.
    Anagnostis P; Siolos P; Christou K; Gkekas NK; Kosmidou N; Athyros VG; Karagiannis A
    Hormones (Athens); 2018 Mar; 17(1):83-95. PubMed ID: 29858866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral semaglutide (Rybelsus) for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
    [No Abstract]   [Full Text] [Related]  

  • 12. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
    Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
    Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
    Katsiki N; Ferrannini E
    J Diabetes Complications; 2020 Dec; 34(12):107723. PubMed ID: 32900588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action.
    Gupta P; Bala M; Gupta S; Dua A; Dabur R; Injeti E; Mittal A
    Pharmacol Res; 2016 Nov; 113(Pt A):636-674. PubMed ID: 27697646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.
    Kuate Defo A; Bakula V; Pisaturo A; Labos C; Wing SS; Daskalopoulou SS
    Diabetes Obes Metab; 2024 Feb; 26(2):441-462. PubMed ID: 37869901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
    Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
    Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.